- Home
- ATAT vs ZLAB Comparison
ATAT vs ZLAB Comparison
Compare ATAT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- ZLAB
- Stock Information
- Founded
- ATAT 2013
- ZLAB 2013
- Country
- ATAT China
- ZLAB China
- Employees
- ATAT N/A
- ZLAB N/A
- Industry
- ATAT Hotels/Resorts
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- ATAT Consumer Discretionary
- ZLAB Health Care
- Exchange
- ATAT Nasdaq
- ZLAB Nasdaq
- Market Cap
- ATAT 3.7B
- ZLAB 3.0B
- IPO Year
- ATAT 2022
- ZLAB 2017
- Fundamental
- Price
- ATAT $25.85
- ZLAB $26.05
- Analyst Decision
- ATAT Strong Buy
- ZLAB Strong Buy
- Analyst Count
- ATAT 2
- ZLAB 3
- Target Price
- ATAT $23.69
- ZLAB $55.00
- AVG Volume (30 Days)
- ATAT 900.1K
- ZLAB 482.4K
- Earning Date
- ATAT 11-19-2024
- ZLAB 02-25-2025
- Dividend Yield
- ATAT 1.74%
- ZLAB N/A
- EPS Growth
- ATAT 162.91
- ZLAB N/A
- EPS
- ATAT 1.20
- ZLAB N/A
- Revenue
- ATAT $950,764,843.00
- ZLAB $355,748,000.00
- Revenue This Year
- ATAT $55.87
- ZLAB $49.04
- Revenue Next Year
- ATAT $25.40
- ZLAB $46.70
- P/E Ratio
- ATAT $21.59
- ZLAB N/A
- Revenue Growth
- ATAT 76.11
- ZLAB 35.01
- 52 Week Low
- ATAT $15.22
- ZLAB $13.48
- 52 Week High
- ATAT $29.90
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- ATAT 46.80
- ZLAB 50.14
- Support Level
- ATAT $24.92
- ZLAB $23.82
- Resistance Level
- ATAT $26.04
- ZLAB $25.64
- Average True Range (ATR)
- ATAT 0.94
- ZLAB 1.24
- MACD
- ATAT -0.14
- ZLAB 0.06
- Stochastic Oscillator
- ATAT 26.56
- ZLAB 64.45
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.